CoChat
Sign Up
Cited by 57

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Recent advances in metabolism and toxicity of tyrosine kinase inhibitors

Zhao, Qi, Wu, Zhanxuan E., Li, Bin, Li, Fei·2022·Pharmacology & Therapeutics
DOI 10.1016/j.pharmthera.2022.108256
Open this paper in CoChat — free account

Abstract

Small molecule tyrosine kinase inhibitors (TKIs) are widely used as anticancer drugs approved by U.S. FDA. However, the toxicities of TKIs to multiple organs have greatly limited their clinical applications. The metabolism of TKIs generates several potentially toxic metabolites in vivo, that can disturb the endogenous metabolism as well as cellular function, leading to organ damage. Therefore, it is essential to identify the toxic metabolites and elucidate the underlying mechanism of TKI-induced toxicity. Metabolomics is a powerful tool for the identification of the xenobiotic metabolites and metabolic derangement associated with xenobiotic exposure, that is helpful to understand the toxicity of TKIs. The study using metabolomics approach has revealed that the reactive metabolites/intermediates (e.g., N-oxide metabolite, primary amine metabolite, 1,4-benzoquinone intermediate) and adducts with glutathione, cysteine and mercapturic acid can be derived from TKIs. Fourteen metabolic pathways could be affected following the TKI treatment, including lipid metabolism, bile acid metabolism, and gut microbiota-related pathway. Modulation of xenobiotic receptor signaling, inhibition of xenobiotic metabolism, and supplementation of endogenous metabolites are potential strategies to protect against TKI-induced toxicity. In this review, studies on the metabolism of TKIs and the alterations of endogenous metabolism are discussed, and the potential preventions against TKI-induced toxicity…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2022.108256

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 8 references

Research works printed but not linked: 238

  1. Abdelgalil, 2020, The protective effect of losartan against sorafenib induced cardiotoxicity: Ex-vivo isolated heart and metabolites profiling studies in rat, European Journal of Pharmacology, 882, 10.1016/j.ejphar.2020.173229 · DOI
  2. Abdelhameed, 2020, Identification of iminium intermediates generation in the metabolism of tepotinib using LC-MS/MS: In silico and practical approaches to bioactivation pathway elucidation, Molecules, 25, 5004, 10.3390/molecules25215004 · DOI
  3. Abdel-Salam, 2014, Citric acid effects on brain and liver oxidative stress in lipopolysaccharide-treated mice, Journal of Medicinal Food, 17, 588, 10.1089/jmf.2013.0065 · DOI
  4. Adaway, 2016, Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement, Annals of Clinical Biochemistry, 53, 554, 10.1177/0004563215613109 · DOI
  5. Agarwal, 2018, Role of L-carnitine in female infertility, Reproductive Biology and Endocrinology, 16, 5, 10.1186/s12958-018-0323-4 · DOI
  6. Akagunduz, 2020, Effects of adenosine triphosphate on vandetanib induced skin damage in rats, Cutaneous and Ocular Toxicology, 39, 323, 10.1080/15569527.2020.1802742 · DOI
  7. Akagunduz, 2021, Protective effects of taxifolin on pazopanib-induced liver toxicity: An experimental rat model, Experimental Animals, 70, 169, 10.1538/expanim.20-0103 · DOI
  8. AlAsmari, 2020, Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways, Saudi Pharmaceutical Journal, 28, 509, 10.1016/j.jsps.2020.03.002 · DOI
  9. Aldemir, 2020, The effect of adenosine triphosphate on sunitinib-induced cardiac injury in rats, Human & Experimental Toxicology, 39, 1046, 10.1177/0960327120909874 · DOI
  10. AlRabiah, 2019, Reactive intermediates in copanlisib metabolism identified by LC-MS/MS: Phase I metabolic profiling, RSC Advances, 9, 6409, 10.1039/C8RA10322D · DOI
  11. Al-Shakliah, 2020, Identification and characterization of in silico, in vivo, in vitro, and reactive metabolites of infigratinib using LC-ITMS: Bioactivation pathway elucidation and in silico toxicity studies of its metabolites, RSC Advances, 10, 16231, 10.1039/C9RA10871H · DOI
  12. Amanuma, 2020, Sorafenib might induce sarcopenia in patients with hepatocellular carcinoma by inhibiting carnitine absorption, Anticancer Research, 40, 4173, 10.21873/anticanres.14417 · DOI
  13. Amaya, 2018, Cytochromes P450 1A2 and 3A4 catalyze the metabolic activation of sunitinib, Chemical Research in Toxicology, 31, 570, 10.1021/acs.chemrestox.8b00005 · DOI
  14. Araki, 2018, Oral intake of royal jelly has protective effects against tyrosine kinase inhibitor-induced toxicity in patients with renal cell carcinoma: A randomized, double-blinded, placebo-controlled trial, Medicines, 6, 2, 10.3390/medicines6010002 · DOI
  15. Aron, 2020, Reproducible molecular networking of untargeted mass spectrometry data using GNPS, Nature Protocols, 15, 1954, 10.1038/s41596-020-0317-5 · DOI
  16. Attwa, 2018, LC-MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: In vivo and in vitro metabolic investigation, Journal of Pharmaceutical and Biomedical Analysis, 160, 19, 10.1016/j.jpba.2018.07.032 · DOI
  17. Attwa, 2018, Identification and characterization of in vivo, in vitro and reactive metabolites of vandetanib using LC-ESI-MS/MS, Chemistry Central Journal, 12, 99, 10.1186/s13065-018-0467-5 · DOI
  18. Baccouch, 2022, The role of the lipid environment in the activity of G protein coupled receptors, Biophysical Chemistry, 285, 10.1016/j.bpc.2022.106794 · DOI
  19. Barbara, 2013, Exploring the utility of high-resolution MS with post-acquisition data mining for simultaneous exogenous and endogenous metabolite profiling, Bioanalysis, 5, 1211, 10.4155/bio.13.102 · DOI
  20. Bauer, 2020, Brain penetration of lorlatinib: Cumulative incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer, Targeted Oncology, 15, 55, 10.1007/s11523-020-00702-4 · DOI
  21. Begriche, 2011, Drug-induced toxicity on mitochondria and lipid metabolism: Mechanistic diversity and deleterious consequences for the liver, Journal of Hepatology, 54, 773, 10.1016/j.jhep.2010.11.006 · DOI
  22. Bello, 2013, A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers, Cancer Chemotherapy and Pharmacology, 72, 379, 10.1007/s00280-013-2207-9 · DOI
  23. Bene, 2018, Role of carnitine and its derivatives in the development and management of type 2 diabetes, Nutrition & Diabetes, 8, 8, 10.1038/s41387-018-0017-1 · DOI
  24. Benkerroum, 2020, Chronic and acute toxicities of aflatoxins: Mechanisms of action, Int J International Journal of Environmental Research and Public Health, 17, 423, 10.3390/ijerph17020423 · DOI
  25. Berger, 2012, Major facilitator superfamily domain-containing protein 2a (MFSD2A) has roles in body growth, motor function, and lipid metabolism, PLoS One, 7, 10.1371/journal.pone.0050629 · DOI
  26. Blanca, 2016, Inflammatory and fibrotic processes are involved in the cardiotoxic effect of sunitinib: Protective role of L-carnitine, Toxicology Letters, 241, 9, 10.1016/j.toxlet.2015.11.007 · DOI
  27. Bolton, 2014, Quinone methide bioactivation pathway: Contribution to toxicity and/or cytoprotection?, Current Organic Chemistry, 18, 61, 10.2174/138527281801140121123046 · DOI
  28. Brkić, 2012, Acyl chain-dependent effect of lysophosphatidylcholine on cyclooxygenase (COX)-2 expression in endothelial cells, Atherosclerosis, 224, 348, 10.1016/j.atherosclerosis.2012.07.038 · DOI
  29. Bruls, 2019, Carnitine supplementation improves metabolic flexibility and skeletal muscle acetylcarnitine formation in volunteers with impaired glucose tolerance: A randomised controlled trial, EBioMedicine, 49, 318, 10.1016/j.ebiom.2019.10.017 · DOI
  30. Cai, 2021, The xenobiotic receptors PXR and CAR in liver physiology, an update, Biochimica et Biophysica Acta, Molecular Basis of Disease, 1867, 10.1016/j.bbadis.2021.166101 · DOI · Paper page
  31. Calzada, 2016, Phosphatidylethanolamine metabolism in health and disease, International Review of Cell and Molecular Biology, 321, 29, 10.1016/bs.ircmb.2015.10.001 · DOI
  32. Carracedo, 2013, Cancer metabolism: Fatty acid oxidation in the limelight, Nature Reviews. Cancer, 13, 227, 10.1038/nrc3483 · DOI
  33. Casares, 2019, Membrane lipid composition: Effect on membrane and organelle structure, function and compartmentalization and therapeutic avenues, International Journal of Molecular Sciences, 20, 2167, 10.3390/ijms20092167 · DOI
  34. Castellino, 2012, Human metabolism of lapatinib, a dual kinase inhibitor: Implications for hepatotoxicity, Drug Metabolism and Disposition, 40, 139, 10.1124/dmd.111.040949 · DOI
  35. Castro, 2019, Targeting metabolic reprogramming in acute myeloid leukemia, Cells, 8, 967, 10.3390/cells8090967 · DOI
  36. Chen, 2020, The underlying mechanisms of lorlatinib penetration across the blood-brain barrier and the distribution characteristics of lorlatinib in the brain, Cancer Medicine, 9, 4350, 10.1002/cam4.3061 · DOI
  37. Chen, 2021, A comprehensive analysis of metabolomics and transcriptomics reveals novel biomarkers and mechanistic insights on lorlatinib crosses the blood-brain barrier, Frontiers in Pharmacology, 12
  38. Cheng, 2019, Biological membrane organization and cellular signaling, Chemical Reviews, 119, 5849, 10.1021/acs.chemrev.8b00439 · DOI
  39. Chintalgattu, 2013, Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity, Science Translational Medicine, 5, 187ra169, 10.1126/scitranslmed.3005066 · DOI
  40. Christopher, 2008, Metabolism and disposition of dasatinib after oral administration to humans, Drug Metabolism and Disposition, 36, 1357, 10.1124/dmd.107.018267 · DOI · Paper page
  41. Collins, 2021, Current challenges and recent developments in mass spectrometry-based metabolomics, Annual Review of Analytical Chemistry, 14, 467, 10.1146/annurev-anchem-091620-015205 · DOI
  42. Cui, 2016, FGF2 prevents sunitinib-induced cardiotoxicity in zebrafish and cardiomyoblast H9c2 cells, Cardiovascular Toxicology, 16, 46, 10.1007/s12012-015-9315-1 · DOI
  43. Cui, 2019, Untargeted LC-MS-based metabonomics revealed that aristolochic acid I induces testicular toxicity by inhibiting amino acids metabolism, glucose metabolism, β-oxidation of fatty acids and the TCA cycle in male mice, Toxicology and Applied Pharmacology, 373, 26, 10.1016/j.taap.2019.04.014 · DOI
  44. Demarquoy, 2014, Biosynthesis, metabolism and function of protectins and resolvins, Clinical Lipidology, 9, 683, 10.2217/clp.14.44 · DOI
  45. Desai, 2017, Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart, Hepatology, 65, 189, 10.1002/hep.28890 · DOI
  46. Dickinson, 2016, Metabolic disposition of osimertinib in rats, dogs, and humans: Insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor, Drug Metabolism and Disposition, 44, 1201, 10.1124/dmd.115.069203 · DOI
  47. Dong, 2019, In vitro metabolism of ibrutinib in rat, dog and human hepatocytes using liquid chromatography combined with diode-array detection and Q-Exactive Orbitrap tandem mass spectrometry, Rapid Communications in Mass Spectrometry, 33, 1804, 10.1002/rcm.8542 · DOI
  48. Du, 2015, NMR-based metabolic profiling reveals neurochemical alterations in the brain of rats treated with sorafenib, Neurotoxicity Research, 28, 290, 10.1007/s12640-015-9539-7 · DOI
  49. Dubbelman, 2015, Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas, Investigational New Drugs, 33, 233, 10.1007/s10637-014-0181-7 · DOI
  50. Eisenberg, 2016, Cardioprotection and lifespan extension by the natural polyamine spermidine, Nature Medicine, 22, 1428, 10.1038/nm.4222 · DOI · Paper page
  51. Fagone, 2013, Phosphatidylcholine and the CDP-choline cycle, Biochimica et Biophysica Acta, 1831, 523, 10.1016/j.bbalip.2012.09.009 · DOI
  52. Ferrero, 2006, Corticosteroids can reverse severe imatinib-induced hepatotoxicity, Haematologica, 91, Ecr27
  53. Fromenty, 1995, Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity, Pharmacology & Therapeutics, 67, 101, 10.1016/0163-7258(95)00012-6 · DOI · Paper page
  54. Fuchs, 2018, Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2(-/-) mice by modulating composition, signalling and excretion of faecal bile acids, Gut, 67, 1683, 10.1136/gutjnl-2017-314553 · DOI · Paper page
  55. Fukumoto, 2017, Novel serum metabolomics-based approach by gas chromatography/triple quadrupole mass spectrometry for detection of human skin cancers: Candidate biomarkers, Journal of Dermatology, 44, 1268, 10.1111/1346-8138.13921 · DOI
  56. Ganesh, 2021, Spatially resolved 3D metabolomic profiling in tissues. Science, Advances, 7, eabd0957
  57. Gao, 2018, The sphingosine 1-phosphate analogue FTY720 alleviates seizure-induced overexpression of P-glycoprotein in rat hippocampus, Basic & Clinical Pharmacology & Toxicology, 123, 14, 10.1111/bcpt.12973 · DOI
  58. Ghassabian, 2012, Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites, Biochemical Pharmacology, 84, 215, 10.1016/j.bcp.2012.04.001 · DOI
  59. Glaenzel, 2020, Absorption, distribution, metabolism, and excretion of capmatinib (INC280) in healthy male volunteers and in vitro aldehyde oxidase phenotyping of the major metabolite, Drug Metabolism and Disposition, 48, 873, 10.1124/dmd.119.090324 · DOI
  60. Gonzalez, 2015, Transgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicity, Expert Opinion on Drug Metabolism & Toxicology, 11, 869, 10.1517/17425255.2015.1032245 · DOI
  61. Gottschalk, 2004, Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells, Clinical Cancer Research, 10, 6661, 10.1158/1078-0432.CCR-04-0039 · DOI
  62. Grisk, 2014, Rho kinase inhibition mitigates sunitinib-induced rise in arterial pressure and renal vascular resistance but not increased renal sodium reabsorption, Journal of Hypertension, 32, 2199, 10.1097/HJH.0000000000000326 · DOI
  63. Gschwind, 2005, Metabolism and disposition of imatinib mesylate in healthy volunteers, Drug Metabolism and Disposition, 33, 1503, 10.1124/dmd.105.004283 · DOI
  64. Guo, 2018, Bile salt hydrolase and s-layer protein are the key factors affecting the hypocholesterolemic activity of lactobacillus casei-fermented milk in hamsters, Molecular Nutrition & Food Research, 62, 10.1002/mnfr.201800728 · DOI
  65. Hadova, 2021, The tyrosine kinase inhibitor crizotinib influences blood glucose and mRNA expression of GLUT4 and PPARs in the heart of rats with experimental diabetes, Canadian Journal of Physiology and Pharmacology, 99, 635, 10.1139/cjpp-2020-0572 · DOI
  66. Hamaguchi, 1991, Interaction of taurine with methionine: Inhibition of myocardial phospholipid methyltransferase, Journal of Cardiovascular Pharmacology, 18, 224, 10.1097/00005344-199108000-00008 · DOI
  67. Han, 2021, A metabolomics pipeline for the mechanistic interrogation of the gut microbiome, Nature, 595, 415, 10.1038/s41586-021-03707-9 · DOI
  68. Hanai, 2020, Usefulness of carnitine supplementation for the complications of liver cirrhosis, Nutrients, 12, 1915, 10.3390/nu12071915 · DOI
  69. Hardwick, 2009, PPAR/RXR regulation of fatty acid metabolism and fatty acid omega-hydroxylase (CYP4) isozymes: Implications for prevention of lipotoxicity in fatty liver disease, PPAR Research, 2009, 10.1155/2009/952734 · DOI
  70. Holten, 2008, Glutamine as a precursor for transmitter glutamate, aspartate and GABA in the cerebellum: A role for phosphate-activated glutaminase, Journal of Neurochemistry, 104, 1032, 10.1111/j.1471-4159.2007.05065.x · DOI
  71. Holzer, 2004, Role of extracellular adenosine triphosphate in human skin, Journal of Cutaneous Medicine and Surgery, 8, 90, 10.1177/120347540400800203 · DOI
  72. van der Hooft, 2017, Unsupervised discovery and comparison of structural families across multiple samples in untargeted metabolomics, Analytical Chemistry, 89, 7569, 10.1021/acs.analchem.7b01391 · DOI
  73. Hu, 2019, The protective roles of PPARalpha activation in triptolide-induced liver injury, Toxicological Sciences, 10.1093/toxsci/kfz146 · DOI
  74. Hu, 2020, Keratinocytes apoptosis contributes to crizotinib induced-erythroderma, Toxicology Letters, 319, 102, 10.1016/j.toxlet.2019.11.007 · DOI
  75. Huxtable, 1973, Effect of taurine on a muscle intracellular membrane, Biochimica et Biophysica Acta, 323, 573, 10.1016/0005-2736(73)90165-X · DOI
  76. Imam, 2020, Protective effect of RIVA against sunitinib-induced cardiotoxicity by inhibiting oxidative stress-mediated inflammation: probable role of TGF-β and smad signaling, Cardiovascular Toxicology, 20, 281, 10.1007/s12012-019-09551-8 · DOI
  77. Inoue, 2012, Unique metabolic pathway of [(14)C]lenvatinib after oral administration to male cynomolgus monkey, Drug Metabolism and Disposition, 40, 662, 10.1124/dmd.111.043281 · DOI
  78. Inoue, 2014, Oxidative metabolic pathway of lenvatinib mediated by aldehyde oxidase, Drug Metabolism and Disposition, 42, 1326, 10.1124/dmd.114.058073 · DOI
  79. Iriyama, 2021, Relationship between carnitine deficiency and tyrosine kinase inhibitor use in patients with chronic myeloid leukemia, Chemotherapy
  80. Ito, 2009, Involvement of transcriptional factor TonEBP in the regulation of the taurine transporter in the cardiomyocyte, Advances in Experimental Medicine and Biology, 643, 523, 10.1007/978-0-387-75681-3_54 · DOI
  81. Jaiyesimi, 2021, Metabolomic profiling of Burkholderia cenocepacia in synthetic cystic fibrosis sputum medium reveals nutrient environment-specific production of virulence factors, Scientifc Reports, 11, 21419, 10.1038/s41598-021-00421-4 · DOI
  82. Jensen, 2017, Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis, British Journal of Pharmacology, 174, 4797, 10.1111/bph.14062 · DOI
  83. Jensen, 2017, Non-targeted metabolomics analysis of the effects of tyrosine kinase inhibitors sunitinib and erlotinib on heart, muscle, liver and serum metabolism in vivo, Metabolites, 7, 31, 10.3390/metabo7030031 · DOI
  84. Jia, 2020, Metagenomic analysis of the human microbiome reveals the association between the abundance of gut bile salt hydrolases and host health, Gut Microbes, 11, 1300, 10.1080/19490976.2020.1748261 · DOI
  85. Jia, 2016, The anti-atherosclerotic effect of tanshinol borneol ester using fecal metabolomics based on liquid chromatography-mass spectrometry, Analyst, 141, 1112, 10.1039/C5AN01970B · DOI
  86. Jin, 2021, Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation, Biomedicine & Pharmacotherapy, 144, 10.1016/j.biopha.2021.112297 · DOI
  87. Johnson, 2015, Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects, Xenobiotica, 45, 45, 10.3109/00498254.2014.941964 · DOI
  88. Joyce, 2014, Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut, Proceedings of the National Academy of Sciences of the United States of America, 111, 7421, 10.1073/pnas.1323599111 · DOI · Paper page
  89. Jump, 2009, Mammalian fatty acid elongases, Methods in Molecular Biology, 579, 375, 10.1007/978-1-60761-322-0_19 · DOI · Paper page
  90. Kadi, 2018, LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: Elucidation of bioactivation pathways, RSC Advances, 8, 1182, 10.1039/C7RA10533A · DOI
  91. Kadi, 2016, Detection and characterization of ponatinib reactive metabolites by liquid chromatography tandem mass spectrometry and elucidation of bioactivation pathways, RSC Advances, 6, 72575, 10.1039/C6RA09985H · DOI
  92. Kalgutkar, 2020, Is there enough evidence to classify cycloalkyl amine substituents as structural alerts?, Biochemical Pharmacology, 174, 10.1016/j.bcp.2020.113796 · DOI
  93. Karakan, 2013, PPAR-alpha agonist treatment increases trefoil factor family-3 expression and attenuates apoptosis in the liver tissue of bile duct-ligated rats, The Turkish Journal of Gastroenterology, 24, 134, 10.4318/tjg.2013.0605 · DOI
  94. Klopcic, 2019, Chemicals and drugs forming reactive quinone and quinone imine metabolites, Chemical Research in Toxicology, 32, 1, 10.1021/acs.chemrestox.8b00213 · DOI
  95. Knottnerus, 2018, Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle, Reviews in Endocrine & Metabolic Disorders, 19, 93, 10.1007/s11154-018-9448-1 · DOI
  96. Kohler, 2016, Analytical pitfalls and challenges in clinical metabolomics, Bioanalysis, 8, 1509, 10.4155/bio-2016-0090 · DOI
  97. Kume, 1992, Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells, The Journal of Clinical Investigation, 90, 1138, 10.1172/JCI115932 · DOI
  98. Kusaczuk, 2019, Tauroursodeoxycholate-bile acid with chaperoning activity: Molecular and cellular effects and therapeutic perspectives, Cells, 8, 1471, 10.3390/cells8121471 · DOI
  99. Lacy, 2015, Metabolism and disposition of cabozantinib in healthy male volunteers and pharmacologic characterization of its major metabolites, Drug Metabolism and Disposition, 43, 1190, 10.1124/dmd.115.063610 · DOI
  100. Lankhorst, 2014, Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: Preclinical study, Hypertension, 64, 1282, 10.1161/HYPERTENSIONAHA.114.04187 · DOI
  101. Lathia, 2006, Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics, Cancer Chemotherapy and Pharmacology, 57, 685, 10.1007/s00280-005-0068-6 · DOI
  102. Latifi, 2019, Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib, Blood, 133, 1597, 10.1182/blood-2018-10-881557 · DOI
  103. Law, 2019, An updated review of lysophosphatidylcholine metabolism in human diseases, International Journal of Molecular Sciences, 20, 1149, 10.3390/ijms20051149 · DOI · Paper page
  104. Lebrin, 2010, Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia, Nature Medicine, 16, 420, 10.1038/nm.2131 · DOI
  105. Lee, 2006, PPAR-gamma agonist increase gefitinib’s antitumor activity through PTEN expression, Lung Cancer, 51, 297, 10.1016/j.lungcan.2005.10.010 · DOI
  106. Li, 2014, Structural identification of imatinib cyanide adducts by mass spectrometry and elucidation of bioactivation pathway, Rapid Communications in Mass Spectrometry, 28, 123, 10.1002/rcm.6758 · DOI
  107. Li, 2012, Metabolomics reveals the metabolic map of procainamide in humans and mice, Biochemical Pharmacology, 83, 1435, 10.1016/j.bcp.2012.02.013 · DOI
  108. Li, 2012, Metabolomics reveals an essential role for peroxisome proliferator-activated receptor alpha in bile acid homeostasis, Journal of Lipid Research, 53, 1625, 10.1194/jlr.M027433 · DOI
  109. Li, 2020, Targeting metabolism in cancer cells and the tumour microenvironment for cancer therapy, Molecules, 25, 4831, 10.3390/molecules25204831 · DOI
  110. Li, 2009, Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways, Drug Metabolism and Disposition, 37, 1242, 10.1124/dmd.108.025932 · DOI
  111. Li, 2009, Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: Implications for pulmonary and hepatic toxicities, Chemical Research in Toxicology, 22, 1736, 10.1021/tx900256y · DOI
  112. Li, 2010, Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile, Drug Metabolism and Disposition, 38, 1238, 10.1124/dmd.109.030361 · DOI
  113. Lin, 2017, Novel pathways of ponatinib disposition catalyzed by CYP1A1 involving generation of potentially toxic metabolites, The Journal of Pharmacology and Experimental Therapeutics, 363, 12, 10.1124/jpet.117.243246 · DOI
  114. Liu, 2012, Protective effects of 7-difluoromethyl-5,4’-dimethoxygenistein against human aorta endothelial injury caused by lysophosphatidyl choline, Molecular and Cellular Biochemistry, 363, 147, 10.1007/s11010-011-1167-9 · DOI
  115. Liu, 2015, Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism, Biochemical Pharmacology, 97, 111, 10.1016/j.bcp.2015.07.010 · DOI
  116. Liu, 2020, Structure-based reactivity profiles of reactive metabolites with glutathione, Chemical Research in Toxicology, 33, 1579, 10.1021/acs.chemrestox.0c00081 · DOI
  117. Liu, 2019, Preventive effect of diallyl trisulfide on cutaneous toxicities induced by EGFR inhibitor, International Immunopharmacology, 69, 79, 10.1016/j.intimp.2019.01.023 · DOI
  118. Ma, 2020, Indole alleviates diet-induced hepatic steatosis and inflammation in a manner involving myeloid cell 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, Hepatology, 72, 1191, 10.1002/hep.31115 · DOI
  119. Ma, 2009, Characterization of imatinib metabolites in rat and human liver microsomes: Differentiation of hydroxylation from N-oxidation by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry, Rapid Communications in Mass Spectrometry, 23, 1446, 10.1002/rcm.4023 · DOI
  120. Madsen, 2018, L-carnitine improves skeletal muscle fat oxidation in primary carnitine deficiency, The Journal of Clinical Endocrinology and Metabolism, 103, 4580, 10.1210/jc.2018-00953 · DOI
  121. Maharsy, 2014, Ageing is a risk factor in imatinib mesylate cardiotoxicity, European Journal of Heart Failure, 16, 367, 10.1002/ejhf.58 · DOI
  122. Majumdar, 2013, Ornithine: The overlooked molecule in the regulation of polyamine metabolism, Plant and Cell Physiology, 54, 990, 10.1093/pcp/pct053 · DOI
  123. Mandard, 2004, Peroxisome proliferator-activated receptor alpha target genes, Cellular and Molcular Life Sciences, 61, 393, 10.1007/s00018-003-3216-3 · DOI
  124. Martínez-Reyes, 2020, Mitochondrial TCA cycle metabolites control physiology and disease, Nature Communications, 11, 102, 10.1038/s41467-019-13668-3 · DOI · Paper page
  125. Marull, 2006, Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers, Journal of Mass Spectrometry, 41, 390, 10.1002/jms.1002 · DOI
  126. Matsubara, 2012, Metabolomics identifies an inflammatory cascade involved in dioxin- and diet-induced steatohepatitis, Cell Metabolism, 16, 634, 10.1016/j.cmet.2012.10.006 · DOI
  127. McCann, 2021, L-carnitine and acylcarnitines: Mitochondrial biomarkers for precision medicine, Metabolites, 11, 51, 10.3390/metabo11010051 · DOI
  128. McKillop, 2004, In vitro metabolism of gefitinib in human liver microsomes, Xenobiotica, 34, 983, 10.1080/02772240400015222 · DOI
  129. Meneses-Lorente, 2021, Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors, Investigational New Drugs, 39, 803, 10.1007/s10637-020-01047-5 · DOI
  130. Mickiewicz, 2016, Serum metabolite profiles are altered by erlotinib treatment and the integrin α1-null genotype but not by post-traumatic osteoarthritis, Journal of Proteome Research, 15, 815, 10.1021/acs.jproteome.5b00719 · DOI
  131. Mingrone, 2013, Use of dicarboxylic acids in type 2 diabetes, Brithish Journal of Clinical Pharmacology, 75, 671, 10.1111/j.1365-2125.2012.04177.x · DOI
  132. Moehring, 2005, Role of poly(ADP-ribose) polymerase activity in imatinib mesylate-induced cell death, Cell Death and Differentiation, 12, 627, 10.1038/sj.cdd.4401608 · DOI
  133. Mokhtari, 2015, Determination of urinary 5-hydroxyindoleacetic acid as a metabolomics in gastric cancer, Journal of Gastrointestinal Cancer, 46, 138, 10.1007/s12029-015-9700-9 · DOI
  134. Mongioi, 2016, The role of carnitine in male infertility, Andrology, 4, 800, 10.1111/andr.12191 · DOI
  135. Morcos, 2017, Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: Results from an absolute bioavailability and mass balance study in healthy subjects, Xenobiotica, 47, 217, 10.1080/00498254.2016.1179821 · DOI
  136. Morita, 2013, Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression, Journal of Hepatology, 59, 292, 10.1016/j.jhep.2013.02.030 · DOI
  137. Mullish, 2019, Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection, Gut, 68, 1791, 10.1136/gutjnl-2018-317842 · DOI · Paper page
  138. Nakagawa, 2018, In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: Contribution of CYP3A enzymes, Xenobiotica, 48, 546, 10.1080/00498254.2017.1344910 · DOI
  139. Neuhofer, 2014, Focal adhesion kinase regulates the activity of the osmosensitive transcription factor TonEBP/NFAT5 under hypertonic conditions, Frontiers in Physiology, 5, 123, 10.3389/fphys.2014.00123 · DOI
  140. Nguyen, 2014, Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid, Nature, 509, 503, 10.1038/nature13241 · DOI · Paper page
  141. Niu, 2020, Ursodeoxycholic acid protects against lung injury induced by fat embolism syndrome, Journal of Cellular and Molecular Medicine, 24, 14626, 10.1111/jcmm.15985 · DOI
  142. Nocerini, 1985, Structure of the glutathione adduct of activated 3-methylindole indicates that an imine methide is the electrophilic intermediate, Drug Metabolism and Disposition, 13, 690, 10.1016/S0090-9556(25)09213-X · DOI
  143. O’Connell, 2020, Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites, European Heart Journal Supplements, 22, J3, 10.1093/eurheartj/suaa115 · DOI
  144. O’Brien, 2005, Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health, Critical Reviews in Toxicology, 35, 609, 10.1080/10408440591002183 · DOI
  145. Ogasawara, 2020, Excretion balance and pharmacokinetics following a single oral dose of [(14)C]-fedratinib in healthy subjects, Cancer Chemotherapy and Pharmacology, 86, 307, 10.1007/s00280-020-04121-0 · DOI
  146. Oladimeji, 2018, PXR: More than just a master xenobiotic receptor, Molecular Pharmacology, 93, 119, 10.1124/mol.117.110155 · DOI
  147. Ona, 2015, Voriconazole N-oxide and its ultraviolet B photoproduct sensitize keratinocytes to ultraviolet A, The British Journal of Dermatology, 173, 751, 10.1111/bjd.13862 · DOI
  148. Ortiz de Montellano, 2019, Acetylenes: Cytochrome P450 oxidation and mechanism-based enzyme inactivation, Drug Metabolism Reviews, 51, 162, 10.1080/03602532.2019.1632891 · DOI
  149. Paludetto, 2018, Metalloporphyrin-catalyzed oxidation of sunitinib and pazopanib, two anticancer tyrosine kinase inhibitors: Evidence for new potentially toxic metabolites, Journal of Medicinal Chemistry, 61, 7849, 10.1021/acs.jmedchem.8b00812 · DOI
  150. Paludetto, 2019, Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug-drug interactions and hepatotoxicity, Medicinal Research Reviews, 39, 2105, 10.1002/med.21577 · DOI
  151. Paludetto, 2019, Involvement of pazopanib and sunitinib aldehyde reactive metabolites in toxicity and drug-drug interactions in vitro and in patient samples, Chemical Research in Toxicology, 33, 181, 10.1021/acs.chemrestox.9b00205 · DOI
  152. Pan, 2021, A serum metabolomic study reveals changes in metabolites during the treatment of lung cancer-bearing mice with anlotinib, Cancer Management and Research, 13, 6055, 10.2147/CMAR.S300897 · DOI
  153. Passi, 1984, Antimitochondrial effect of saturated medium chain length (C8-C13) dicarboxylic acids, Biochemical Pharmacology, 33, 103, 10.1016/0006-2952(84)90376-9 · DOI
  154. Patel, 2015, Characterization of forced degradation products of pazopanib hydrochloride by UHPLC-Q-TOF/MS and in silico toxicity prediction, Journal of Mass Spectrometry, 50, 918, 10.1002/jms.3602 · DOI
  155. Patel, 2019, Novel use of N-acetylcysteine in management of tyrosine kinase inhibitor induced acute liver injury, Cureus, 11
  156. Pegg, 2014, The function of spermine, IUBMB Life, 66, 8, 10.1002/iub.1237 · DOI
  157. Pegg, 2010, Spermine synthase, Cellular and Molecular Life Sciences, 67, 113, 10.1007/s00018-009-0165-5 · DOI
  158. Pelleg, 1997, Autonomic neural control of cardiac function: Modulation by adenosine and adenosine 5'-triphosphate, The American Journal of Cardiology, 79, 11, 10.1016/S0002-9149(9X)00257-5 · DOI
  159. Phan, 2014, Cancer metabolic reprogramming: Importance, main features, and potentials for precise targeted anti-cancer therapies, Cancer Biology & Medicine, 11, 1
  160. Podoll, 2019, Bioavailability, biotransformation, and excretion of the covalent bruton tyrosine kinase inhibitor acalabrutinib in rats, dogs, and humans, Drug Metabolism and Disposition, 47, 145, 10.1124/dmd.118.084459 · DOI
  161. Poliakova, 2018, The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer, Molecular Cancer, 17, 27, 10.1186/s12943-018-0798-9 · DOI
  162. Poliaková, 2019, Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET-activating mutations-driven models, The FEBS Journal, 286, 2692, 10.1111/febs.14852 · DOI
  163. Quinn, 2016, Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome, The ISME Journal, 10, 1483, 10.1038/ismej.2015.207 · DOI
  164. Rao, 2013, Acyl chain-dependent effect of lysophosphatidylcholine on endothelium-dependent vasorelaxation, PLoS One, 8, 10.1371/journal.pone.0065155 · DOI
  165. Rappez, 2019, Spatial single-cell profiling of intracellular metabolomes in situ, BioRxiv
  166. Ren, 2021, Sodium-glucose cotransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK-mTOR signaling pathway-mediated autophagy, Frontiers in Pharmacology, 12, 10.3389/fphar.2021.664181 · DOI
  167. Ribas, 2014, L-carnitine supplementation as a potential antioxidant therapy for inherited neurometabolic disorders, Gene, 533, 469, 10.1016/j.gene.2013.10.017 · DOI
  168. Rimola, 2020, Lysophospholipids contribute to oxaliplatin-induced acute peripheral pain, The Journal of Neuroscience, 40, 9519, 10.1523/JNEUROSCI.1223-20.2020 · DOI
  169. Rinschen, 2019, Identification of bioactive metabolites using activity metabolomics, Nature Reviews Molecular Cell Biology, 20, 353, 10.1038/s41580-019-0108-4 · DOI · Paper page
  170. Rood, 2021, Extrahepatic metabolism of ibrutinib, Investigational New Drugs, 39, 1, 10.1007/s10637-020-00970-x · DOI
  171. Sa Santos, 2011, The role of glia in neuronal recovery following anoxia: In vitro evidence of neuronal adaptation, Neurochemistry International, 58, 665, 10.1016/j.neuint.2011.02.005 · DOI
  172. Samuni, 2013, The chemistry and biological activities of N-acetylcysteine, Biochimica et Biophysica Acta, 1830, 4117, 10.1016/j.bbagen.2013.04.016 · DOI · Paper page
  173. Sarszegi, 2012, BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases, Molecular and Cellular Biochemistry, 365, 129, 10.1007/s11010-012-1252-8 · DOI
  174. Satoh, 1998, Review of some actions of taurine on ion channels of cardiac muscle cells and others, General Pharmacology, 30, 451, 10.1016/S0306-3623(97)00309-1 · DOI
  175. Sayed-Ahmed, 2019, Carnitine supplementation attenuates sunitinib-induced inhibition of AMP-activated protein kinase downstream signals in cardiac tissues, Cardiovascular Toxicology, 19, 344, 10.1007/s12012-018-9500-0 · DOI
  176. Schaffer, 2010, Physiological roles of taurine in heart and muscle, Journal of Biomedical Science, 17, S2, 10.1186/1423-0127-17-S1-S2 · DOI
  177. Scheers, 2015, Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: An open-label, phase I, single-dose study in healthy men, Drug Metabolism and Disposition, 43, 289, 10.1124/dmd.114.060061 · DOI
  178. Schulz, 2013, Progressive stages of mitochondrial destruction caused by cell toxic bile salts, Biochimica et Biophysica Acta, 1828, 2121, 10.1016/j.bbamem.2013.05.007 · DOI
  179. Shah, 2013, Hepatotoxicity of tyrosine kinase inhibitors: Clinical and regulatory perspectives, Drug Safety, 36, 491, 10.1007/s40264-013-0048-4 · DOI
  180. Shaw, 2017, Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: An international, multicentre, open-label, single-arm first-in-man phase 1 trial, Lancet Oncology, 18, 1590, 10.1016/S1470-2045(17)30680-0 · DOI
  181. Shen, 2019, Downregulation of miR-146a contributes to cardiac dysfunction induced by the tyrosine kinase inhibitor sunitinib, Frontiers in Pharmacology, 10, 914, 10.3389/fphar.2019.00914 · DOI
  182. Shindo, 2019, Can levocarnitine supplementation improve fatigue caused by sunitinib as a treatment for renal cell carcinoma? A single-center prospective pilot study, Supportive Care in Cancer, 27, 1491, 10.1007/s00520-018-4521-6 · DOI
  183. Siim, 2004, Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317, Cancer Research, 64, 736, 10.1158/0008-5472.CAN-03-2488 · DOI
  184. Smith, 2014, Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans, Drug Metabolism and Disposition, 42, 918, 10.1124/dmd.113.056531 · DOI
  185. Speed, 2012, Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans, Drug Metabolism and Disposition, 40, 539, 10.1124/dmd.111.042853 · DOI
  186. Streidl, 2021, The gut bacterium Extibacter muris produces secondary bile acids and influences liver physiology in gnotobiotic mice, Gut Microbes, 13, 1, 10.1080/19490976.2020.1854008 · DOI
  187. Stypinski, 2020, Metabolism, excretion, and pharmacokinetics of lorlatinib (PF-06463922) and evaluation of the impact of radiolabel position and other factors on comparability of data across 2 ADME studies, Journal of Clinical Pharmacology, 60, 1254, 10.1002/jcph.1621 · DOI
  188. Sun, 2021, Icotinib induces mechanism-based inactivation of recombinant human CYP3A4/5 possibly via heme destruction by ketene intermediate, Drug Metabolism and Disposition, 49, 892, 10.1124/dmd.121.000369 · DOI
  189. Swaminathan, 2012, Calmodulin-dependent protein kinase II: Linking heart failure and arrhythmias, Circulation Research, 110, 1661, 10.1161/CIRCRESAHA.111.243956 · DOI
  190. Takahashi, 2015, Absorption, metabolism, excretion, and the contribution of intestinal metabolism to the oral disposition of [14C]cobimetinib, a MEK inhibitor, in humans, Drug Metabolism and Disposition, 44, 28, 10.1124/dmd.115.066282 · DOI
  191. Takahashi, 2017, Absorption, metabolism and excretion of cobimetinib, an oral MEK inhibitor, in rats and dogs, Xenobiotica, 47, 50, 10.3109/00498254.2016.1157645 · DOI
  192. Takakusa, 2011, Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib, Drug Metabolism and Disposition, 39, 1022, 10.1124/dmd.110.037531 · DOI
  193. Tan, 2020, Emerging roles of lysophospholipids in health and disease, Progress in Lipid Research, 80, 10.1016/j.plipres.2020.101068 · DOI
  194. Tang, 2022, Direct and sequential bioactivation of pemigatinib to reactive iminium ion intermediates culminate in mechanism-based inactivation of cytochrome P450 3A, Drug Metabolism and Disposition, 10.1124/dmd.121.000804 · DOI
  195. Teng, 2010, Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib, Molecular Pharmacology, 78, 693, 10.1124/mol.110.065839 · DOI
  196. Teo, 2013, Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis, Cancer Treatment Reviews, 39, 199, 10.1016/j.ctrv.2012.09.004 · DOI
  197. Teo, 2015, Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: A literature review, Expert Opinion on Drug Metabolism & Toxicology, 11, 231, 10.1517/17425255.2015.983075 · DOI
  198. Terasaki, 2019, Molecular hydrogen attenuates gefitinib-induced exacerbation of naphthalene-evoked acute lung injury through a reduction in oxidative stress and inflammation, Laboratory Investigation, 99, 793, 10.1038/s41374-019-0187-z · DOI
  199. Tomita, 2012, Increases in bioavailability of poorly absorbed drug by acylcarnitine, Journal of Pharmaceutical Sciences, 101, 3511, 10.1002/jps.23214 · DOI
  200. Torok, 2015, Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: A MALDI-MS imaging study, British Journal of Pharmacology, 172, 1148, 10.1111/bph.12990 · DOI

200 of 238 shown

Cited by

Sorted by citations

See all 57

Metadata

Authors
Zhao, Q., Wu, Z. E., Li, B., & Li, F.
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2022-09
Volume
237
Pages
108256
ISSN
0163-7258
DOI
10.1016/j.pharmthera.2022.108256
Cited by
57
References
8
Language
en
Licence
Funders
  • Sichuan University (2021HXBH041)
  • National Key Research and Development Program of China
  • Fundamental Research Funds for the Central Universities (2022SCU12054)
  • National Key Research and Development Program of China Stem Cell and Translational Research (2021YFF0702000)
  • West China Hospital, Sichuan University
  • National Natural Science Foundation of China (81360509)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review